AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated ...

AstraZeneca’s rare disease company Alexion said the trial met its first co-primary endpoint.

April 21 () - AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met ‌the main goal of a late-stage trial ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare ...

A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary ...

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...

A pre-clinical study published in The Lancet on June 25 found that mixing AstraZeneca with a second dose of Pfizer provides "robust" protection from severe COVID-19. The pre-clinical study was ...

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...